

RESEARCH

Open Access



The effect of probiotic-fortified kefir on cardiovascular risk factors in elderly population: a double-blind, randomized, placebo-controlled clinical trial

Mehran Noori^{1*†}, Zainab Shateri^{2†}, Siavash Babajafari³, Mohammad Hadi Eskandari⁴, Karim Parastouei¹, Mohammad Ghasemi¹, Hoseein Afshari⁵ and Mohammad Samadi^{6*}

Abstract

Introduction The outbreak of cardiovascular disease (CVD) augments with age. Gut dysbiosis can worsen or initiate systemic disorders such as metabolic diseases and CVDs. Therefore, this research aimed to assess the effect of kefir fortified with *Lactobacillus helveticus* R0052 and *Bifidobacterium longum* R017 on CVD risk factors in the elderly population. The subjects of this study were selected from the Motahari Clinic in Shiraz, Iran.

Method This study was a double-blind, randomized, and controlled clinical trial that was conducted on 67 elderly people who were randomly divided into two groups: the fortified kefir group ($n=32$), which received one bottle of fortified kefir (240 cc), and the placebo group ($n=35$), which received one bottle of regular kefir for eight weeks. To analyze the data, SPSS software was applied.

Results After eight weeks, significant differences were seen in atherogenic and Castell's risk index I between the fortified and regular groups ($p=0.048$ and $p=0.048$, respectively). No significant differences were found in Castell's risk index II, high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides (TG), non-HDL-C, TG-cholesterol index, and fasting blood sugar by comparing the two groups.

Conclusion Our investigation demonstrated that fortified kefir with probiotics did not significantly affect lipid profiles. Still, it could significantly affect some indices, including Castell's risk index I and atherogenic index. More studies are required to confirm the findings and mechanisms of probiotics' effect on CVD risk factors.

Trial number The present registered at the Iranian Registry of Clinical Trials (IRCT20130227012628N3) at 2023-02-21.

Keywords Kefir, Probiotics, *Bifidobacterium*, *Lactobacillus*, Lipid profile

[†]Mehran Noori and Zainab Shateri equally contributed to this work.

*Correspondence:

Mehran Noori
mehran.nouri71@gmail.com
Mohammad Samadi
samadi.mohammad@yahoo.com

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Today, due to technological and medical advances, people's life expectancy has increased, which has led to an increase in the average age of society and an increase in the elderly population [1, 2]. "Elderly" refers to a person aged 65 or older [3]. The outbreak of cardiovascular disease (CVD) risk factors augments with age [4]. CVD is one of the most common causes of death worldwide, estimated to have caused 17.8 million deaths worldwide in 2017 [5, 6]. In 1960, the most common causes of death in Iran were diarrheal and infectious diseases, and in the last few decades, it has shifted to CVDs [6]. The growing epidemic of CVDs may be due to insufficient physical activity, urbanization and industrialization, dietary changes, cultural and socio-economic changes, increased life expectancy, and increased metabolic risk factors [6]. Other risk factors for CVDs include obesity, smoking, diabetes, dyslipidemia, and hypertension [7].

Studies have indicated a relationship between gut microbiota and the function of various host organs. Gut dysbiosis can worsen or initiate systemic disorders such as metabolic diseases and CVDs [8, 9]. This issue has led to an increased interest in using probiotics, whose studies suggest their role in preventing intestinal dysbiosis and maintaining intestinal homeostasis [10–12]. A study on rats indicated that milk products fermented by *Bifidobacterium longum*, a probiotic species, can improve lipid profile [13]. It has also been shown that milk fermented with a species of bacteria called *Lactobacillus helveticus* can effectively reduce blood pressure in animal models [14].

Kefir, which is milk fermented from a combination of yeast and bacteria, is the most widely utilized and has attracted the most attention [15]. Various studies have shown that fermented milk with kefir grains can play a role in lowering blood pressure [16, 17]. Also, a study showed that kefir could help reduce hemoglobin A_{1c} (HbA_{1c}) and blood sugar in patients with type 2 diabetes mellitus. Further, the mentioned research did not show any significant relationship between kefir consumption and lipid profile [18]. However, another study illustrated that kefir consumption can effectively lower lipid profiles and blood pressure in metabolic syndrome [19].

There are some conflicting studies on the relationship between kefir and CVD risk factors. Also, to our knowledge, there has been no research on kefir fortified with two types of bacteria, *Bifidobacterium longum* and *Lactobacillus helveticus*, in elderly subjects. Therefore, this study aimed to investigate the effect of kefir fortified with *Bifidobacterium longum* and *Lactobacillus helveticus* on CVD risk factors in the elderly population.

Methods

Trial design

This research was a parallel, randomized, double-blind, and controlled clinical trial. Using G*Power software with $d=0.75$, $\alpha=0.05$, and $\beta=80\%$ based on the previous study [20], the sample size was computed for the total antioxidant capacity [21] variable (unpublished data). Therefore, 29 subjects were needed to participate in each group. Considering 20% removal or violation of protocols, 36 participants were required for each fortified and regular kefir groups. The present study was confirmed by the Baqiyatallah Hospital Ethics Committee (ethical no.: IR.BMSU.BAQ.REC.1401.113) and registered at the Iranian Registry of Clinical Trials (IRCT20130227012628N3) at 2023-02-21 (The secondary data of this clinical trial that registered in Iranian Registry of Clinical Trials were reported in the present study).

A permuted-block randomization was used for participants' randomization with a fixed block size of four by a computer (2:2 ratio). Allocation and randomization were masked from participants and researchers. A trained assistant randomly allocated subjects to fortified and regular kefir groups. To follow a double-blind design, the kefir manufacturing company was asked to code the bottles. Also, each participant was assigned a code to keep the participants' information confidential. Each participant completed a checklist of personal characteristics and demographic information. At the beginning of the study, height was measured. Also, weight, waist circumference [22], hip circumference (HC), and body mass index (BMI) (weight (kg)/ height (m)²) were measured at the start and the end of the study. Seca Germany device was used to measure weight, and non-stretchable and fixed tape was used to measure participants' height. Participants were asked not to change their usual diet and physical activity during this study. To assess participants' physical activity, the International Physical Activity Questionnaire (IPAQ) was utilized [23]. The subjects were classified into three groups based on their physical activity level: high: > 3000 metabolic equivalent of tasks (METs)-minutes/week, moderate: 600–3000 METs-minutes/week, and low: < 600 METs-minutes/week. Questionnaires were completed, and blood samples were taken at the beginning and end of the study (after eight weeks). Also, dietary intake was assessed at the beginning and after eight weeks of intervention by a three-day dietary record. Initially, all food portion sizes were changed to grams [24], and then, energy, micronutrients, and macronutrients were calculated by the Nutritionist IV [25].

To regularly consume kefir, we sent reminder messages to all participants, and all participants had to record their kefir consumption every day. Also, the participants were

requested to return to the clinic after two weeks to get the next kefir. In addition, all subjects signed informed consent at the beginning of the research.

Participants

The subjects of this study were selected from the Motahari Clinic in Shiraz, Iran. The participants were only elderly men over 65 years of age. Medical history, lifestyle, drugs, and social information were completed using a checklist. Also, the participants were asked to consume kefir regularly, and how to consume it was explained to them.

The inclusion criteria of our study were the following items: male gender, age > 65 years, BMI > 25, without any history of diseases such as diabetes, CVDs, digestive disorders, chronic infectious diseases, not consuming antibiotics and probiotics in the last two months and not drinking alcohol and smoking.

The present study's exclusion criteria included changing diet and medication, taking other probiotic supplements, kefir side effects, and being unwilling to continue the research.

Intervention

Kefir fortified with probiotics and placebo (kefir without added probiotics (regular kefir)) were prepared by Pegah Company, Fars, Iran. The shape, size, and packaging of the two types of kefir were the same. Each bottle of probiotic-fortified kefir (240 cc) contained *Lactobacillus helveticus* R0052 and *Bifidobacterium longum* R0175 (dosage 3×10^9 colony-forming unit (CFU) for each) (The starter culture of kefir consisted of *LAF4* and *Kluyveromyces marxianus*). In the placebo group, participants received 240 cc of regular kefir simultaneously. The participants were asked to consume a bottle of kefir daily with lunch or dinner for eight weeks. Subjects who consumed less than 80% of kefir were excluded from our research.

Outcomes

Measurement of non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), triglycerides (TG), HDL-C, fasting blood sugar (FBS), Castelli's risk index I, atherogenic index, TG-glucose index, and Castelli's risk index II were the primary outcomes of this study, which were evaluated at the start and the end of the 8th week.

Blood sample collection

Ten mL of fasting (eight hours) blood samples were taken from all subjects at the beginning and end of the study. Then, blood samples were centrifuged at 3000 revolutions per minute (rpm) speed for 7 min, and for further biochemical assessment in the future, isolated serums were frozen at -76°C .

Laboratory analyses

We used enzymatic kits (Pars Azmoon, Tehran, Iran) for measuring lipid profiles and FBS. Also, some indices were calculated based on the bottom formula:

Castelli's risk index II: low-density lipoprotein cholesterol (LDL-C) (mg/dL) / HDL-C (mg/dL).

Castelli's risk index I: TC (mg/dL) / HDL-C (mg/dL).

TG-glucose index: $\ln [\text{fasting TG (mg/dL)} \times \text{fasting plasma glucose (mg/dL)} / 2]$

Atherogenic index: non-HDL-C (mg/dL) to HDL-C (mg/dL).

Non-HDL-C: TC (mg/dL) - HDL-C (mg/dL).

Statistical analysis

We used the Mann-Whitney U-test and the independent sample T-test for the two groups' nutrient and cardiovascular risk factor variables. Also, the Mann-Whitney U-test was used for continuous variables, and the chi-square test assessed the qualitative features of the baseline variables. Moreover, the paired sample T-test and Wilcoxon U-test were used for within-group analysis. In addition, the Kolmogorov-Smirnov test was applied to assess the normality of the variables. To analyze the data, SPSS software was applied. A $p < 0.05$ was considered a level of significance.

Results

After eight weeks of fortified and regular kefir supplementation, 67 overweight and obese elderly subjects completed the trial (35 people in the regular kefir group and 32 people in the fortified kefir group). The reasons for excluding people are shown in Fig. 1.

The participants' demographic and anthropometric features of the study are shown in Table 1. According to this table, the difference in anthropometric and demographic features between the two groups was not significant ($p > 0.05$ for all).

The study population's nutrient intake at the start and after eight weeks of kefir supplementation is reported in Table 2. By comparing the two groups, there was no significant difference in macro- and micronutrient intake at the beginning and after eight weeks of kefir supplementation ($p > 0.05$ for all). Also, within-group analysis showed no significant difference in all nutrient intake in the fortified and regular kefir groups ($p > 0.05$ for all).

Table 3 shows the effect of fortified and regular kefir on CVD risk factors. At the study's baseline, there was no significant difference in CVD risk factors between the two groups ($p > 0.05$ for all). However, after eight weeks, significant differences were seen in atherogenic and Castelli's risk index I between the fortified and regular groups ($p = 0.048$ and $p = 0.048$, respectively). Further, in within-group analysis, a significant reduction was seen in TG ($p = 0.015$), atherogenic ($p = 0.012$), TG-glucose index




Fig. 1 Flowchart of the study

($p=0.001$), Castell's risk index I ($p=0.012$), FBS level ($p=0.029$), and Castell's risk index II ($p<0.001$) in the fortified kefir group. In addition, in the regular kefir group, a significant decrease was found in Castell's risk index II ($p<0.001$) and FBS level ($p=0.011$).

Discussion

The present clinical trial evaluated the impact of the fortified kefir with probiotics on CVD risk factors in the elderly population. No significant effect was observed with probiotic-fortified kefir consumption compared to regular kefir on Castelli's risk index II, non-HDL-C, TC, TG, HDL-C, TG-cholesterol index, and FBS based on the comparison between the two groups. Only Castelli's risk index I and atherogenic index decreased significantly in the fortified kefir group after the intervention compared to the regular kefir group. However, the TG-glucose index, Castell's risk index I, atherogenic index, and TG significantly reduced after the intervention in the fortified-kefir group. Also, FBS and Castell's risk index II decreased significantly after intervention in both groups.

The findings of our study revealed that fortified kefir with probiotics had no significant effect on variables such as non-HDL-C, HDL-C, TC, and TG. Various studies have been conducted regarding the impact of probiotics on lipid profile, some of which demonstrated that their consumption could improve the lipid profile [26, 27], and some indicated that their consumption did not affect the lipid profile [28, 29]. A clinical trial study on the impact of probiotics in subjects with non-alcoholic fatty liver

disease revealed that probiotic consumption (*Streptococcus thermophilus* and *Lactobacillus bulgaricus*) for three months had no significant effect on HDL-C, LDL-C, TC, and TG [29]. Also, Firouzi. et al. demonstrated that consuming several strains of probiotics, including *B. longum*, in people with type 2 diabetes for 12 weeks had no significant impact on HDL-C, LDL-C, TC, and TG [30].

Studies have shown probiotic foods may reduce serum lipid concentrations [31]. Gilliland et al. found that some strains of *Lactobacillus acidophilus* might reduce cholesterol uptake by binding to cholesterol in the intestinal tract [32]. Also, probiotics can reduce cholesterol by hydrolyzing bile salt and thus deconjugating it and connecting with cholesterol and co-precipitation of cholesterol with deconjugated bile acids [33]. In addition, some probiotics utilize cholesterol in their metabolism [18]. In the current study, both groups received kefir, which contains probiotic living microorganisms, and only in the kefir-fortified group, in addition to other probiotics in kefir, did they also receive two other probiotic strains. The presence of probiotics in kefir, the small sample size and the short duration of the intervention may be the reasons for not observing a significant change in the lipid profile.

The current research findings indicated a significant decrease in Castell's risk index I and atherogenic index in the comparison of the two groups. In a randomized clinical trial, a significant decrease in TC/HDL-C ratio was found after supplementation with probiotics (*Lactobacillus fermentum*, *Lactobacillus reuteri*,

Table 1 Anthropometric and demographic features of the study population at the baseline and end of the study (n = 67)

Variables	Fortified kefir group (n = 32)	Regular kefir group (n = 35)	P-value
Age (year) ¹	65.00 (65.00–66.00)	65.00 (65.00–65.00)	0.375
Weight [40] ¹			
Before	77.00 (73.00–85.00)	77.00 (72.00–85.00)	0.93
After	76.00 (73.00–84.00)	77.00 (72.00–83.00)	0.895
Height (cm) ¹	170.00 (165.00–174.50)	170.00 (165.00–173.00)	0.924
BMI (kg/m ²) ¹			
Before	26.44 (25.31–28.63)	27.28 (25.30–29.38)	0.935
After	26.10 (25.22–28.05)	26.44 (25.09–28.90)	0.93
Waist circumference (cm) ¹			
Before	99.00 (97.00–105.75)	99.00 (97.00–107.00)	0.915
After	98.50 (96.00–102.00)	98.00 (97.00–104.00)	0.668
Hip circumference (cm) ¹			
Before	103.00 (101.00–109.75)	103.00 (100.00–113.00)	0.91
After	100.00 (98.00–106.50)	100.00 (98.00–110.00)	0.905
WHR ¹			
Before	0.96 (0.96–0.97)	0.96 (0.96–0.97)	0.86
After	0.98 (0.96–0.98)	0.97 (0.97–0.98)	0.93
Physical activity, % ²			0.806
Low	19 (59.40)	22 (62.90)	
Moderate	13 (40.60)	13 (37.10)	
Education Level, % ²			0.771
Less than diploma	8 (25.00)	7 (20.00)	
Diploma and more	24 (75.00)	28 (80.00)	
Smoking history, % ²			0.584
Yes	7 (21.90)	10 (28.60)	
No	25 (78.10)	25 (71.40)	
Disease history, % ²			0.787
Yes	10 (31.30)	9 (25.70)	
No	22 (68.80)	26 (74.30)	
Medication, % ²			1
Yes	10 (31.30)	11 (31.40)	
No	22 (68.70)	24 (68.60)	

- BMI: body mass index, WHR: waist-to-hip ratio, kg: kilogram, cm: centimeter, kg/m: kilogram / meter²

-Using Mann-Whitney U-test for continuous and chi-square test for categorical variables

¹Values are median (25th -75th)

²Values are number (percent)

Bifidobacterium bifidum, and *Lactobacillus acidophilus*) for 12 weeks in patients with diabetic nephropathy [34]. Also, another randomized controlled trial illustrated that kefir decreased significantly TC/ HDL-C ratio after eight weeks in obese or overweight premenopausal women [35]. Moreover, Chan et al. found that a multi-strain probiotic mixture decreased atherosclerotic plaque development and inflammation in ApoE^{-/-} mice [36]. Hypercholesterolemia, which refers to elevated blood cholesterol, is a major risk factor for atherosclerosis, which causes stroke and myocardial infarction [37, 38]. Reduction in TC significantly reduces the risk of CVDs [39]. Human probiotic microorganisms that have been well-studied for their cholesterol-lowering impacts in animals and humans are mostly related to the genera

Bifidobacterium and *Lactobacillus* [40]. The mechanism of probiotics lowering cholesterol is not yet fully understood [41]. However, it has been shown that some probiotics and their metabolites can hinder the synthesis and absorption of cholesterol and cholesterol breakdown [42].

The findings indicated a significant reduction in the fortified-kefir group's TG-glucose index, Castelli's risk index I, atherogenic index, and TG. A study by Rosa et al. demonstrated that kefir supplementation could decrease liver TG, plasma TG, and fasting glucose in a metabolic syndrome's animal model [43]. Also, Mafi et al., in a randomized trial showed probiotic supplements could decrease fasting plasma glucose and TG [34]. Moreover, another research by Zavišić et al. has shown

Table 3 Nutrient intake of the study population at the baseline and end of the study (n = 67)
The effect of fortified and regular kefir on cardiovascular risk factors (n = 67)

Variables	Fortified kefir group (n = 32)	Regular kefir group (n = 35)	P-value ³
TG (mg/dL) ¹			
Before	174.50 (115.00-217.50)	146.00 (122.00-202.00)	0.555
After	133.00 (104.00-155.75)	174.00 (113.00-225.00)	0.105
P-value ⁴	0.015	0.857	
TC (mg/dL) ²			
Before	159.16 ± 27.00	162.43 ± 42.08	0.709
After	155.25 ± 32.39	161.40 ± 35.69	0.462
P-value ⁴	0.529	0.847	
HDL-C (mg/dL) ²			
Before	34.00 ± 6.85	34.06 ± 7.01	0.973
After	36.13 ± 10.09	33.80 ± 6.76	0.268
P-value ⁴	0.18	0.829	
Non-HDL-C ²			
Before	125.15 ± 25.11	128.37 ± 38.52	0.69
After	119.12 ± 26.41	127.60 ± 33.18	0.255
P-value ⁴	0.244	0.866	
Atherogenic index ²			
Before	3.80 ± 1.01	3.85 ± 1.33	0.853
After	3.40 ± 0.77	3.86 ± 1.07	0.048
P-value ⁴	0.012	0.967	
TG-glucose index ²			
Before	9.04 ± 0.58	9.01 ± 0.78	0.844
After	8.68 ± 0.61	8.83 ± 0.52	0.284
P-value ⁴	0.001	0.155	
Castelli's risk index I ²			
Before	4.80 ± 1.01	4.85 ± 1.33	0.853
After	4.40 ± 0.77	4.86 ± 1.07	0.048
P-value	0.012	0.967	
Castelli's risk index II ²			
Before	3.76 ± 1.01	4.09 ± 1.43	0.295
After	2.56 ± 0.63	2.75 ± 0.71	0.251
P-value ⁴	>0.001	>0.001	
FBS (mg/dL) ¹			
Before	100.00 (88.25-110.75)	97.00 (89.00-110.00)	0.615
After	86.00 (73.25-99.25)	82.00 (73.00-102.00)	0.797
P-value ⁴	0.029	0.011	

TG: triglycerides, TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, FBS: fasting blood sugar

¹Values are median (25th-75th)

²Values are mean ± SD

³Using Mann-Whitney U-test for non-parametric and independent sample T-test for parametric variables

⁴Using Wilcoxon U-test for non-parametric and paired sample T-test for parametric variables

Table 2 (continued)

that supplementing mice with metabolic syndrome with probiotics (*Lactobacillus helveticus* and *Lactobacillus rhamnosus*) reduced their serum TG and blood sugar levels [44]. Probiotics can effectively lower blood glucose levels through the inhibition of cytokines and reactive oxygen metabolite production that can destroy beta cells [45]. Also, probiotics can stimulate the production of glucagon-like peptides and insulinotropic polypeptides by acting on the bacteria and thus cause muscle glucose absorption [22]. The probiotics' mechanism action can also be caused by their effect on the peroxisome proliferator-activated receptor- α (PPAR- α), has a critical role in the transport and oxidation of fatty acids. Also, probiotics can upregulate apolipoprotein, which significantly determines serum TG levels [46].

This research is the first one that investigated the effect of kefir fortified with two particular strains of probiotics on risk factors of CVD in Iranian elderly. Also, the double-blind and placebo-controlled research design was one of the strengths of the current study. However, due to limited financial resources, we could not examine the participants' microbiomes, and we could not determine whether the consumption of prebiotics caused a change in their composition.

Conclusions

Our investigation demonstrated that fortified kefir with probiotics did not significantly affect lipid profiles. Still, it could significantly affect some indices, including the Castelli's risk index I and atherogenic index. More studies are required to confirm the findings and mechanisms of probiotics' effect on CVD risk factors.

Acknowledgements

We thank all participants in the current study.

Author contributions

Mehran Noori; Contributed to writing the first draft. Zainab Shateri; Contributed to writing the first draft. Siavash Babajafari; Contributed to statistical analysis and interpretation of data. Mohammad Hadi Eskandari; Contributed to statistical analysis and interpretation of data. Karim Parastouei; Contributed to statistical analysis and interpretation of data. Mohammad Ghasemi; Contributed to supervising the work, study concept, and edited the manuscript. Hoseein Afshari; Contributed to statistical analysis and interpretation of data. Mohammad Samadi; Contributed to statistical analysis, interpretation of data, supervising the work, study concept, and edited the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Human Ethics approval and

The current research was approved by the Medical Research and Ethics Committee of Baqiyatallah Hospital (IR.BMSU.BAQ.REC.1401.113) and

registered at the Iranian Registry of Clinical Trials (IRCT20130227012628N3) at 2023-02-21 and was carried out in accordance with the ethical standards of the Declaration of Helsinki.

Consent to participate

The informed consents were completed by all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

²Department of Nutrition and Biochemistry, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran

³Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Science, Shiraz University of Medical Sciences, Shiraz, Iran

⁴Department of Food Science and Technology, School of Agriculture, Shiraz University, Shiraz, Iran

⁵Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁶Exercise Physiology Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Received: 19 December 2023 / Accepted: 26 April 2024

Published online: 13 May 2024

References

1. Fakhrazadeh H, Sharifi F. Cardiovascular diseases in the elderly. *J Gorgan Univ Med Sci*. 2012;14(3):1–9.
2. Khalagi K, Ansarifard A, Fahimfar N, Sanjari M, Gharibzadeh S, Sharifi F, Shafiee G, Heshmat R, Nabipour I, Larjani B, et al. Cardio-metabolic and socio-demographic risk factors associated with dependency in basic and instrumental activities of daily living among older Iranian adults: Bushehr elderly health program. *BMC Geriatr*. 2021;21(1):172.
3. Singh S, Bajorek B. Defining 'elderly' in clinical practice guidelines for pharmacotherapy. *Pharm Pract* 2014, 12(4).
4. Leritz EC, McGlinchey RE, Kellison I, Rudolph JL, Milberg WP. Cardiovascular disease risk factors and cognition in the elderly. *Curr Cardiovasc risk Rep*. 2011;5:407–12.
5. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of Disease Study 2017. *Lancet*. 2018;392(10159):1736–88.
6. Sarrafzadegan N, Mohammadifard N. Cardiovascular Disease in Iran in the last 40 years: Prevalence, Mortality, Morbidity, challenges and Strategies for Cardiovascular Prevention. *Arch Iran Med*. 2019;22(4):204–10.
7. Ciomănean L, Milaciu MV, Negrean V, Orășan OH, Vesa SC, Sălăgean O, Iluț S, Vlaicu SI. Cardiovascular risk factors and physical activity for the prevention of cardiovascular diseases in the elderly. *Int J Environ Res Public Health*. 2021;19(1):207.
8. Claesson MJ, Clooney AG, O'toole PW. A clinician's guide to microbiome analysis. *Nat Reviews Gastroenterol Hepatol*. 2017;14(10):585–95.
9. Powell N, Walker MM, Talley NJ. The mucosal immune system: master regulator of bidirectional gut–brain communications. *Nat Reviews Gastroenterol Hepatol*. 2017;14(3):143–59.
10. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? *Nat Reviews Gastroenterol Hepatol*. 2017;14(1):9–21.
11. Vitetta L, Saltzman ET, Nikov T, Ibrahim I, Hall S. Modulating the gut micro-environment in the treatment of intestinal parasites. *J Clin Med*. 2016;5(11):102.
12. Rosa DD, Dias MM, Grześkowiak ŁM, Reis SA, Conceição LL. Maria do Carmo GP: milk kefir: nutritional, microbiological and health benefits. *Nutr Res Rev*. 2017;30(1):82–96.
13. Xiao J, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, Iwatsuki K, Kokubo S, Hosono A. Effects of milk products fermented by *Bifidobacterium longum* on blood lipids in rats and healthy adult male volunteers. *J Dairy Sci*. 2003;86(7):2452–61.
14. Chen Y, Liu W, Xue J, Yang J, Chen X, Shao Y, Kwok L-y, Bilige M, Mang L, Zhang H. Angiotensin-converting enzyme inhibitory activity of *Lactobacillus helveticus* strains from traditional fermented dairy foods and antihypertensive effect of fermented milk of strain H9. *J Dairy Sci*. 2014;97(11):6680–92.
15. Pimenta FS, Luaces-Regueira M, Ton AM, Campagnaro BP, Campos-Toimil M, Pereira TM, Vasquez EC. Mechanisms of action of kefir in chronic cardiovascular and metabolic diseases. *Cell Physiol Biochem*. 2018;48(5):1901–14.
16. Kanbak G, Uzuner K, Kuşat Ol K, Oğlakçı A, Kartkaya K, Şentürk H. Effect of kefir and low-dose aspirin on arterial blood pressure measurements and renal apoptosis in unihypertensive rats with 4 weeks salt diet. *Clin Exp Hypertens*. 2014;36(1):1–8.
17. Maeda H, Zhu X, Suzuki S, Suzuki K, Kitamura S. Structural characterization and biological activities of an exopolysaccharide kefir produced by *Lactobacillus kefirifaciens* WT-2BT. *J Agric Food Chem*. 2004;52(17):5533–8.
18. Ostadrahimi A, Taghizadeh A, Mobasser M, Farrin N, Payahoo L, Gheshlaghi ZB, Vahedjabbari M. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. *Iran J Public Health*. 2015;44(2):228.
19. da Silva Ghizi AC, de Almeida Silva M, de Andrade Moraes FS, da Silva CL, Endringer DC, Scherer R, Lenz D, de Lima EM, Brasil GA, Maia JF. Kefir improves blood parameters and reduces cardiovascular risks in patients with metabolic syndrome. *PharmaNutrition*. 2021;16:100266.
20. Noorifard M, Moghaddam AD, Asemi Z, Farahani RH, Jazayeri SMM, Ebrahimi E. Effect of Probiotic supplementation on Oxidative Stress Enzymes and Mental Health of Athletes. *Annals Military Health Sci Res* 2019, 17(1).
21. Chen L-K, Liu L-K, Woo J, Assantachai P, Auyeung T-W, Bahyah KS, Chou M-Y, Chen L-Y, Hsu P-S, Krairit O. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95–101.
22. Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. *Eur J Drug Metab Pharmacokinet*. 2008;33:101–6.
23. Biernat E, Stupnicki R, Lebiecziński B, Janczewska L. Assessment of physical activity by applying IPAQ questionnaire. *Phys Educ Sport*. 2008;52(2):83–9.
24. Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran: Nashre Olume Keshavarzy. 1999;7(213):42–58.
25. Nutritionist I. N-squared computing. Silverton: Nutritionist IV 1998.
26. Pereira DI, Gibson GR. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. *Crit Rev Biochem Mol Biol*. 2002;37(4):259–81.
27. Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Mogharri A. Effect of probiotic yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium lactis* on lipid profile in individuals with type 2 diabetes mellitus. *J Dairy Sci*. 2011;94(7):3288–94.
28. Sadrazadeh-Yeganeh H, Elmadfa I, Djazayeri A, Jalali M, Heshmat R, Chamary M. The effects of probiotic and conventional yoghurt on lipid profile in women. *Br J Nutr*. 2010;103(12):1778–83.
29. Aller R, De Luis D, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in non-alcoholic fatty liver disease patients: a double blind randomized clinical trial. *Eur Rev Med Pharmacol Sci*. 2011;15(9):1090–5.
30. Firozi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak M-Y. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. *Eur J Nutr*. 2017;56:1535–50.
31. Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, Chakraborty C, Singh B, Marotta F, Jain S. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. *Journal of Diabetes Research* 2012, 2012.
32. Gilliland S, Walker D. Factors to consider when selecting a culture of *Lactobacillus acidophilus* as a dietary adjunct to produce a hypocholesterolemic effect in humans. *J Dairy Sci*. 1990;73(4):905–11.
33. Gilliland S, Nelson C, Maxwell C. Assimilation of cholesterol by *Lactobacillus acidophilus*. *Appl Environ Microbiol*. 1985;49(2):377–81.
34. Mafi A, Namazi G, Soleimani A, Bahmani F, Aghadavod E, Asemi Z. Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. *Food Funct*. 2018;9(9):4763–70.

35. Fathi Y, Ghodrati N, Zibaenezhad M-J, Faghih S. Kefir drink causes a significant yet similar improvement in serum lipid profile, compared with low-fat milk, in a dairy-rich diet in overweight or obese premenopausal women: a randomized controlled trial. *J Clin Lipidol*. 2017;11(1):136–46.
36. Chan YK, El-Nezami H, Chen Y, Kinnunen K, Kirjavainen PV. Probiotic mixture VSL# 3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE^{-/-} mice. *Amb Express*. 2016;6(1):1–8.
37. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. *Lancet*. 2020;396(10263):1644–52.
38. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha J-K, Ducrocq G, Giroud M. A comparison of two LDL cholesterol targets after ischemic stroke. *N Engl J Med*. 2020;382(1):9–19.
39. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. *J Am Coll Cardiol*. 2018;72(10):1141–56.
40. Miremadi F, Sherkat F, Stojanovska L. Hypocholesterolaemic effect and anti-hypertensive properties of probiotics and prebiotics: a review. *J Funct Foods*. 2016;25:497–510.
41. Ishimwe N, Daliri EB, Lee BH, Fang F, Du G. The perspective on cholesterol-lowering mechanisms of probiotics. *Mol Nutr Food Res*. 2015;59(1):94–105.
42. Liang X, Zhang Z, Zhou X, Lu Y, Li R, Yu Z, Tong L, Gong P, Yi H, Liu T. Probiotics improved hyperlipidemia in mice induced by a high cholesterol diet via downregulating FXR. *Food Funct*. 2020;11(11):9903–11.
43. Rosa DD, Grześkowiak ŁM, Ferreira CL, Fonseca ACM, Reis SA, Dias MM, Siqueira NP, Silva LL, Neves CA, Oliveira LL. Kefir reduces insulin resistance and inflammatory cytokine expression in an animal model of metabolic syndrome. *Food Funct*. 2016;7(8):3390–401.
44. Zavišić G, Ristić S, Rikalović M, Petković B, Janković D, Vukadinović A, Petričević S. Beneficial effects of probiotic supplementation on glucose and triglycerides in a mouse model of metabolic syndrome. *J Funct Foods*. 2022;95:105167.
45. Alihosseini N, Moahboob S, Farrin N, Mobasser M, Taghizadeh A, Ostadrahimi A. Effect of probiotic fermented milk (kefir) on serum level of insulin and homocysteine in type 2 diabetes patients. *Acta Endocrinol (Bucharest)*. 2017;13(4):431.
46. Choi I-D, Kim S-H, Jeong J-W, Lee DE, Huh C-S, Hong SS, Sim J-H, Ahn Y-T. Triglyceride-lowering effects of two probiotics, *Lactobacillus plantarum* KY1032 and *Lactobacillus curvatus* HY7601, in a rat model of high-fat diet-induced hypertriglyceridemia. *J Microbiol Biotechnol*. 2016;26(3):483–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.